canertinib has been researched along with Esophageal Neoplasms in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ako, E; Hirakawa, K; Hori, T; Kubo, N; Ohira, M; Sawada, T; Yamashita, Y; Yamazaki, M | 1 |
1 other study(ies) available for canertinib and Esophageal Neoplasms
Article | Year |
---|---|
The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo.
Topics: Animals; Carcinoma, Squamous Cell; Cell Proliferation; ErbB Receptors; Esophageal Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2007 |